Recursion Pharmaceuticals acquires Exscientia: A merger to accelerate drug discovery

Recursion Pharmaceuticals has submitted a binding offer to acquire Exscientia in order to combine their complementary portfolios and technology platforms, thereby advancing the discovery and development of new drugs. Shareholders of Exscientia are invited to vote on the proposed arrangement, which provides for the exchange of each Exscientia share for 0.7729 shares of Recursion Class A common stock. The success of this acquisition depends on the approval of the shareholders of both companies. A special meeting has been convened for this purpose on November 12, 2024.